PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth of 0.49% while Biotechnology median is zero. Walter Schloss might see a slight advantage that could be built upon.
56.85%
EBIT growth of 56.85% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
54.90%
Operating income growth of 54.90% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
56.85%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
56.86%
EPS growth exceeding 1.5x Biotechnology median of 2.38%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
56.86%
Diluted EPS growth exceeding 1.5x Biotechnology median of 2.27%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Biotechnology median is 1.70%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Biotechnology median is 1.90%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth of 28.81% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
28.81%
FCF growth exceeding 1.5x Biotechnology median of 0.31%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.99%
OCF/share CAGR exceeding 1.5x Biotechnology median of 23.59% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
56.40%
OCF/share CAGR of 56.40% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-114.69%
Negative 3Y OCF/share CAGR while Biotechnology median is 16.22%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
96.39%
Net income/share CAGR exceeding 1.5x Biotechnology median of 59.90% over a decade. Joel Greenblatt might see a standout compounder of earnings.
45.76%
5Y net income/share CAGR > 1.5x Biotechnology median of 24.80%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
32.63%
3Y net income/share CAGR 75-90% of Biotechnology median. John Neff would seek cost or revenue improvements to match peers.
-96.80%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-86.34%
Negative 5Y equity/share growth while Biotechnology median is -20.25%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-81.50%
Negative 3Y equity/share growth while Biotechnology median is -55.84%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-26.00%
Negative BV/share change while Biotechnology median is -5.27%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-9.98%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-36.64%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-70.64%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.